Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine: Non-inferiority Clinical Trial (FIBROSTIM)
A legfontosabb adatok
- Ki végzi
- Hospital de Clinicas de Porto Alegre
- Hol
- Brazília1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 610 fő, tervezett
- Kezdés
- 2025. szept. 30.
- Várható befejezés
- 2028. dec.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Transcranial direct current stimulation (tDCS) plus placebo.
- Duloxetine (60 mg) once daily
- Home-based transcranial direct current stimulation
- Duloxetine 60 mg
- A regiszteradat frissítve
- 2026. január 6.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for right-handed women with fibromyalgia who have moderate or worse pain. It compares home brain stimulation (tDCS) with the drug duloxetine.
- Életkor
- 18 to 75 years
- Nem
- Women only
- A betegség stádiuma
- Fibromyalgia diagnosed by the American College of Rheumatology (ACR) 2010-2016 criteria. Pain score of 4 or more (Numeric Pain Scale) on most days in the past 30 days.
- Korábbi kezelés
- People cannot join if they take duloxetine at more than 60 mg/day. People must agree not to change medicine doses during the trial, except pain relievers.
A részvétel fő kizáró okai
- Living more than 250 km (155 mérföld) from Porto Alegre
- Pregnancy
- Metal implants or devices in the brain, cardiac pacemaker or cochlear implant
- Neurological disorders, brain injury or brain surgery in the past
- Alcohol or drug abuse in the past 6 months, chronic inflammatory rheumatic disease, or active cancer under treatment
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Woman aged between 18 and 75 years
- Right-handed
- Literate in reading and writing
- Clinical diagnosis of fibromyalgia based on the American College of Rheumatology (ACR) 2010-2016 criteria
- Numeric Pain Scale (NPS) score ≥ 4 on most days in the past 30 days
- Agree no changes in medication dosage during the treatment period (except for analgesics)
- Able to swallow tablets
- Able to understand instructions for using tDCS at home
Ki nem vehet részt
- Alcohol or drug abuse in the past 6 months
- Metal implants in the brain
- Cochlear implant
- Decompensated systemic diseases
- Chronic inflammatory rheumatologic diseases
- Active cancer under treatment
- Decompensated psychiatric disorders with suicide risk and a defined plan
- Cardiac pacemaker
- Neurological disorders
- History of traumatic brain injury or neurosurgery
- Living more than 250 km from Porto Alegre
- Pregnancy
- Untreated hypothyroidism
- Use of duloxetine at a dose > 60 mg/day
- Implanted brain medical devices
Egyéb feltételek
- Eligibility Criteria
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Brazília.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
Fibromyalgia is characterized by widespread pain, fatigue, non-restorative sleep, and psychocognitive alterations, compromising quality of life and leading to absenteeism and early retirement. Up to 70% of patients discontinue treatment with antidepressants and anticonvulsants due to adverse effects or low efficacy, and more than 30% resort to opioid use. Given the treatment challenges and the scarcity of safe alternatives, there is growing interest in interventions such as transcranial direct current stimulation (tDCS), which has shown efficacy in improving symptoms and functionality, with low cost and few side effects. In this context, we designed a randomized, double-blind, double-dummy clinical trial to compare the non-inferiority of 28 home-based anodal tDCS (2 mA) applied over the primary motor cortex (M1) versus duloxetine 60 mg. Both treatments will be combined with physical exercise and pain education. Outcomes will be assessed through multidimensional measures of pain, functionality, global impression of improvement, and the function of the descending pain inhibitory system. Secondary outcomes include quality of life, depressive symptoms, psychophysical pain measures, and treatment adherence. An additional analysis will compare the results of sham tDCS and duloxetine placebo within the non-inferiority model. Predictors of treatment response will also be explored, including symptom severity and oscillatory patterns of cortical electrical activity, rest-activity rhythm, and autonomic function assessed by R-R interval. Furthermore, serum levels of S100-B protein, brain-derived neurotrophic factor (BDNF), and genetic variants related to neuroplasticity in the BDNF Val66Met, Catechol-O-Methyltransferase (COMT) (rs4680) (G>A), OPRM1, and PER2 genes will be analyzed. Inflammatory markers (TNF-α, IL-1, IL-2, IL-6, IL-10, C-reactive protein) and serum endorphins will also be assessed. A total of 610 women with fibromyalgia (aged 18 to 75 years) will be randomized into three groups (2:2:1): duloxetine + sham tDCS (n=244); active tDCS + placebo (n=244); and sham tDCS + placebo (n=122). Participants will be assessed during treatment and at 3, 6, and 12 months after completing the intervention protocol. An interim analysis will be conducted when ~50% of participants (n ≈ 305) complete the 3-month follow-up by an independent, blinded Data Monitoring Committee (DMC). (i) The trial may be stopped if the conditional probability of demonstrating non-inferiority is <10%, based on frequentist or Bayesian methods. (i) The trial will be stopped if serious adverse events (SAEs) in the active tDCS group increase by ≥30% compared to duloxetine (p < 0.01, adjusted). (ii) Early stopping for efficacy will be considered if active tDCS demonstrates clear non-inferiority or superiority over duloxetine on the primary outcome. Superiority requires: (iii) a clinically relevant difference exceeding the non-inferiority margin (≥10% pain reduction); (ii) statistical significance (p < 0.005, O'Brien-Fleming adjusted); and (iii) a ≥2-point (20%) improvement on the BPI, confirmed in the ITT analysis. This study aims to generate evidence to support the decision-making process of the National Committee for Health Technology Incorporation (CONITEC) regarding the availability of tDCS in the Brazilian Unified Health System (SUS). In addition, identifying predictors of response to tDCS and duloxetine, through the integration of genetic, neurophysiological, inflammatory, and psychosocial markers using machine learning algorithms, will allow for identifying factors that can personalize fibromyalgia treatment. This approach enhances clinical efficacy, reduces costs associated with ineffective interventions, and supports more accurate therapeutic decisions, expanding access to safe, effective, and sustainable care within the public healthcare system
A vizsgálat 3 csoportja
- (s-tDCS over M1+placebo medication) - Home-Based Transcranial Direct Current Stimulation (tDCS)Színlelt kezelés, összehasonlításként
The sham tDCS protocol will use the same electrode montage as the active tDCS, with active current delivered for 30 seconds at the beginning, after 10 minutes, and at the end of the session. The current will be applied using 35 cm² electrodes.
Kezelés: Transcranial direct current stimulation (tDCS) plus placebo. és Home-based transcranial direct current stimulation
- The study includes 28 sessions of home-based anodal transcranial direct current stimulation (tDCS)A vizsgált kezelés
Active anodal tDCS (2 mA) or sham tDCS will be applied over the left M1 (anode) and the right supraorbital area (cathode) for 20 minutes, combined with physical exercises and educational guidance on pain neuroscience for fibromyalgia. After in-person training, participants will receive instructions for home use.
Kezelés: Transcranial direct current stimulation (tDCS) plus placebo. és Home-based transcranial direct current stimulation
- Duloxetine 60 mgMár használt kezelés, összehasonlításként
The pharmacological intervention will use duloxetine (30 mg and 60 mg), commercially acquired. The medication and placebo will be sourced via contracts with a compounding pharmacy and a retail drugstore. Generic Duloxetine Hydrochloride (Germed) will be purchased and sent for fractioning and placebo preparation. Each participant will receive a kit with four jars (duloxetine or placebo): Jar 01 (white lid): 7 × 30 mg - Week 1 (run-in); Jar 02 (green lid): 16 × 60 mg - Weeks 2-3 (run-in); Jar 03 (green lid): 42 × 60 mg - During tDCS; Jar 04 (white lid): 7 × 30 mg - Post-treatment taper.
Kezelés: Duloxetine (60 mg) once daily és Duloxetine 60 mg
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Home-based Transcranial Direct Current Stimulation (tDCS) Compared to Duloxetine in the Treatment of Fibromyalgia: a Randomized Non-inferiority Clinical Trial (FIBROSTIM)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07203339: ki vehet részt
- A regiszteradat frissítve
- 2026. január 6.